AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)
Pakistan

Pakistan to receive China's CanSino COVID-19 vaccine for commercial sale this week

  • It is expected that the first 10,000 doses will reach Pakistan on March 25, and 100,000 more doses by next month
  • Trial results show that CanSino vaccine is 65.7 percent effective in preventing symptomatic COVID-19 cases and has 90.98 percent success rate in stopping severe infections
Published March 22, 2021

(Karachi) Pakistan is all set to receive shipments of China’s CanSino Biologics coronavirus vaccine for commercial sale this week, local media reported on Monday.

An official of AJ Pharma said it is expected that the first 10,000 doses will reach Pakistan on March 25, and 100,000 more doses by next month. He added that 200,000 CanSino vaccine doses will be shipped in May.

Earlier, health officials said the single-dose Chinese vaccine could be administered to people of all ages as it was found effective among people from 18 to 80 plus years of age during trials in Pakistan and other countries of the world.

They disclosed that the CanSino Biologics Inc.’s vaccine would also be ‘manufactured partially in Pakistan,’ following its successful conclusion of trials at five leading health institutions in the country.

The registration board of Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) had given emergency use authorization to CanSino Biologics’s single-dose vaccine in the second week of February 2021 after the Chinese manufacturer released interim efficacy results from a multi-country trial, which included Pakistan, showing 65.7 percent efficacy in preventing symptomatic COVID-19 cases and a 90.98 percent success rate in stopping severe infections.

Comments

Comments are closed.